-
Je něco špatně v tomto záznamu ?
Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab
E. Svabova, J. Zieg, M. Sukova, E. Flachsova, M. Kment, V. Tesar
Jazyk angličtina Země Německo
Typ dokumentu kazuistiky, časopisecké články
Grantová podpora
00064203
Ministerstvo Zdravotnictví Ceské Republiky
NLK
ProQuest Central
od 1996-08-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1996-08-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1996-08-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1996-08-01 do Před 1 rokem
Family Health Database (ProQuest)
od 1996-08-01 do Před 1 rokem
- MeSH
- antigeny CD38 imunologie analýza MeSH
- biopsie MeSH
- imunoglobulin G * krev MeSH
- ledviny patologie imunologie účinky léků MeSH
- lidé MeSH
- membranoproliferativní glomerulonefritida * farmakoterapie imunologie patologie MeSH
- mladiství MeSH
- monoklonální protilátky * terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
There is no specific treatment for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID), a disease that is very rare in the pediatric population. We report the case of a 15-year-old boy who presented with mildly reduced kidney function and nephrotic syndrome. Kidney biopsy revealed PGNMID with monoclonal deposits of IgG3 with kappa light chain restriction. Flow cytometry showed a significant CD38 plasma cell population in the peripheral blood in the absence of other signs of hematological malignancy. The patient was treated with a 6-month course of daratumumab, a monoclonal antibody targeting CD38. There was a significant reduction in proteinuria and normalization of kidney function. Based on positive experience with adults, daratumumab should also be studied in children with PGNMID.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003331
- 003
- CZ-PrNML
- 005
- 20250206104251.0
- 007
- ta
- 008
- 250121s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00467-024-06425-2 $2 doi
- 035 __
- $a (PubMed)38858270
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Svabova, Eva $u Department of Pediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. eva.svabova@fnmotol.cz
- 245 10
- $a Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab / $c E. Svabova, J. Zieg, M. Sukova, E. Flachsova, M. Kment, V. Tesar
- 520 9_
- $a There is no specific treatment for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID), a disease that is very rare in the pediatric population. We report the case of a 15-year-old boy who presented with mildly reduced kidney function and nephrotic syndrome. Kidney biopsy revealed PGNMID with monoclonal deposits of IgG3 with kappa light chain restriction. Flow cytometry showed a significant CD38 plasma cell population in the peripheral blood in the absence of other signs of hematological malignancy. The patient was treated with a 6-month course of daratumumab, a monoclonal antibody targeting CD38. There was a significant reduction in proteinuria and normalization of kidney function. Based on positive experience with adults, daratumumab should also be studied in children with PGNMID.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a imunoglobulin G $x krev $7 D007074
- 650 12
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 12
- $a membranoproliferativní glomerulonefritida $x farmakoterapie $x imunologie $x patologie $7 D015432
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a ledviny $x patologie $x imunologie $x účinky léků $7 D007668
- 650 _2
- $a antigeny CD38 $x imunologie $x analýza $7 D051997
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zieg, Jakub $u Department of Pediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Sukova, Martina $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Flachsova, Eva $u Department of Pediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Kment, Martin $u Department of Clinical and Transplant Pathology, Institute of Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Tesar, Vladimir $u Department of Nephrology, First Faculty of Medicine, General University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00003733 $t Pediatric nephrology $x 1432-198X $g Roč. 39, č. 12 (2024), s. 3455-3457
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38858270 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104247 $b ABA008
- 999 __
- $a ok $b bmc $g 2263226 $s 1239338
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 39 $c 12 $d 3455-3457 $e 20240611 $i 1432-198X $m Pediatric nephrology $n Pediatr Nephrol $x MED00003733
- GRA __
- $a 00064203 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20250121
